ArticleClinical research in cardiology : official journal of the German Cardiac Society2024
Ultra-long-term efficacy and safety of catheter-based renal denervation in resistant hypertension: 10-year follow-up outcomes.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- Renal Safety of Distal Renal Denervation on Kidney Function in Diabetic Patients with Resistant Hypertension.Medicina (Kaunas, Lithuania) · 2026Trial
- Renal Denervation in Cardiovascular Diseases: Mechanisms, Evidence, and Expanding Applications.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Review
- Renal denervation revisited: is patient selection the missing link between failure and success?Clinical hypertension · 2026Review
- Association between arterial stiffness and long-term efficacy of renal sympathetic denervation: 5-year results of the ASORAS study.Cardiovascular intervention and therapeutics · 2026Article
- Ten-Year Results of Therapeutic Intravascular Ultrasound Renal Denervation in Resistant Hypertension: A Prospective Single-Center Study.Kidney & blood pressure research · 2026Article
- Renal denervation for hypertension.Nature reviews. Cardiology · 2025Review
- Key Updates to the 2024 ESC Hypertension Guidelines and Future Perspectives.Medicina (Kaunas, Lithuania) · 2025Review
- Balancing Affordability and Need: Should We Use Renal Denervation in Hypertension Management?Journal of the Society for Cardiovascular Angiography & Interventions · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRandomized sham-controlled trials have confirmed the efficacy and safety of catheter-based renal denervation in hypertension. Data on the very long-term effects of renal denervation are scarce.
aimsThis study evaluates the 10-year safety and efficacy of renal denervation in resistant hypertension.
methodsThis prospective single-center study included patients with resistant hypertension undergoing radio-frequency renal denervation between 2010 and 2012. Office blood pressure, 24-h ambulatory blood pressure, antihypertensive medication, color duplex sonography, and renal function were assessed after 1-, 2- and 10-years.
resultsThirty-nine patients completed the 10-year follow-up (mean follow-up duration 9.4 ± 0.7 years). Baseline office and 24-h ambulatory systolic blood pressure were 164 ± 23 mmHg and 153 ± 16 mmHg, respectively. After 10 years, 24-h ambulatory and office systolic blood pressure were reduced by 16 ± 17 mmHg (P < 0.001) and 14 ± 23 mmHg (P = 0.001), respectively. The number of antihypertensive drugs remained unchanged from 4.9 ± 1.4 to 4.5 ± 1.2 drugs (P = 0.087). The estimated glomerular filtration rate declined within the expected range from 69 (95% CI 63 to 74) to 60 mL/min/1.73m
conclusionRenal denervation was safe and sustainedly reduced ambulatory and office blood pressure out to 10 years in patients with resistant hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.